Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMW542E)

Drug Name
Orphenadrine Drug Info
Synonyms
Antiflex; Biorphen; Brocadisipal; Brocasipal; Disipal; Lysantin; Mefenamine; Mephenamine; Methyldiphenylhydramine; Myolin; Myotrol; ORP; Orfenadrina; Orfro; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrinum; Orphenate; Orphenedrine; Norflex Orphenadrine Citrate; Sodium Mefenamine; WS 2434; Banflex (TN); Biorphen (TN); Brocasipal (TN); Disipal (TN); Flexon (TN); Mephenamin (TN); Mialgin (TN); Norflex (TN); O-Methyldiphenhydramine; O-Monomethyldiphenhydramine; Orfenadrina [INN-Spanish]; Orphenadrine(INN); Orphenadrine [INN:BAN]; Orphenadrinum [INN-Latin]; Beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Phenyl-o-tolylmethyl dimethyaminoethyl ether; Beta-Dimethylaminoethyl-2-methylbenzhydryl ether; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin; N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine; N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine; N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine; N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine
Therapeutic ClassAntiparkinson Agents
Cross-matching ID
PubChem CID
4601
ChEBI ID
CHEMBL900
CAS Number
CAS 83-98-7
TTD Drug ID
D0D9FV
VARIDT Drug ID
DR00835
ACDINA Drug ID
D00492

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
GnRH secretion 2.05 0.00e+0 60/64 (93.75%) KCNN2;ITPR1;PRKCA;...
Non-homologous end-joining 1.91 2.60e-2 11/13 (84.62%) DCLRE1C;FEN1;DNTT;...
Estrogen signaling pathway 1.89 2.17e-2 119/137 (86.86%) KRT15;KRT14;SRC;...
Growth hormone synthesis, secretion and action 1.78 4.42e-2 108/119 (90.76%) ITPR1;PRKCA;GNAI1;...
Ribosome -1.66 4.00e-2 113/158 (71.52%) MRPL2;RPL26;RPL24;...
Prion disease -1.67 4.09e-2 209/273 (76.56%) TNF;PSMD11;PSMC6;...
Thermogenesis -1.76 1.20e-2 173/232 (74.57%) SDHA;SIRT6;MAP2K3;...
Proteasome -1.78 9.52e-3 44/46 (95.65%) PSMD11;PSMC6;PSMD13;...
Sulfur metabolism -1.80 7.32e-3 9/10 (90%) SELENBP1;ETHE1;TST;...
Huntington disease -1.83 7.32e-3 233/306 (76.14%) PSMD11;PSMC6;CREB3;...
Porphyrin and chlorophyll metabolism -1.87 2.09e-3 23/43 (53.49%) UGT2B28;UGT2B17;UGT2A3;...
Amyotrophic lateral sclerosis -1.88 2.44e-3 267/364 (73.35%) ATP5PB;EIF2S1;NDUFS8;...
Linoleic acid metabolism -1.88 2.93e-3 21/29 (72.41%) CYP1A2;CYP2J2;CYP2C9;...
Ferroptosis -1.89 3.66e-3 36/41 (87.8%) TP53;NCOA4;GCLM;...
Parkinson disease -2.08 2.44e-3 176/249 (70.68%) PSMA5;PSMA1;PSMB2;...
Oxidative phosphorylation -2.20 0.00e+0 93/133 (69.92%) ATP12A;ATP5MC3;COX7A2L;...
Mineral absorption -2.56 0.00e+0 48/60 (80%) ATP1A2;ATP1B2;MT2A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 6.66uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H